Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2026-01-04 @ 5:06 PM
Study NCT ID:
NCT01237951
Status:
COMPLETED
Last Update Posted:
2020-05-05
First Post:
2010-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myeloma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Autologous Hematopoietic-Cell Support | View |
| None | Stem Cell Transplant | View |
| None | Busulfan | View |
| None | Myleran | View |
| None | Busulfex | View |
| None | Gemcitabine | View |
| None | Gemzar | View |
| None | Melphalan | View |
| None | Alkeran | View |
| None | Decadron | View |
| None | Dexamethasone | View |
| None | G-CSF | View |
| None | Filgrastim | View |
| None | Neupogen | View |